NTFS

Brainstorm Cell Therapeutics Announces Grant of a New Brazilian Patent Covering Methods of Manufacturing NurOwn®

Retrieved on: 
Tuesday, February 15, 2022
Amyotrophic lateral sclerosis, NASDAQ, EMA, Orphan drug, Food, European Medicines Agency, Company, California Institute for Regenerative Medicine, Neurodegeneration, California Institute for Quantitative Biosciences, Phrase, NGF, MS, Annual report, IP, Adult, Safety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, Cell, NTFS, CIRM, National, FDA, Regenerative medicine, BDNF, Patent, HGF, Research, Hepatocyte growth factor, VEGF, GDNF, Multiple sclerosis, Microsoft, Nerve growth factor, Vaccine, Pharmaceutical industry, Brainstorm, ALS, EU

"We are committed to the development of NurOwn as a potential treatment for ALS and other neurodegenerative diseases.

Key Points: 
  • "We are committed to the development of NurOwn as a potential treatment for ALS and other neurodegenerative diseases.
  • This patent, which covers the industrial manufacturing process for NurOwn developed by Brainstorm's scientists, enhances our ability to do so worldwide," said Chaim Lebovits, Chief Executive Officer, Brainstorm Cell Therapeutics.
  • The NurOwn technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders.
  • Brainstorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.

Crypto Inu Introduces a DeFi Deflationary Token with Charity Support

Retrieved on: 
Thursday, February 10, 2022
Crypto, NFT, School, Disc jockey, VR, NTFS, City, ABCD, Decentralized finance, Monopoly, 3D, Cryptocurrency

The team at Crypto Inu has announced the release of its token to the crypto community, which combines non-custodial staking with charity support.

Key Points: 
  • The team at Crypto Inu has announced the release of its token to the crypto community, which combines non-custodial staking with charity support.
  • Crypto Inu incorporates real estate investment into its metaverse using its DeFi deflationary token.
  • Crypto Inu aims to give players, content creators, and crypto enthusiasts an NFT real estate game where they can earn by investing in real estate and assets management.
  • However, unlike the Monopoly game, Crypto Inu comes integrated with a social aspect where users can interact with other players.

BrainStorm Cell Therapeutics to Present at the 12th Annual California ALS Research Summit

Retrieved on: 
Thursday, January 27, 2022
California Institute for Regenerative Medicine, Regenerative medicine, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Amyotrophic lateral sclerosis, Annual report, CIRM, FDA, Association, Orphan drug, Research, NTFS, Adult, Phrase, NASDAQ, Food, Company, Brainstorm, EMA, European Medicines Agency, ALS Association, National, Multiple sclerosis, MHSC, Neurodegeneration, MS, Badminton Association of India, Safety, Microsoft, Pharmaceutical industry, ALS

NEW YORK, Jan. 27, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Ralph Kern, M.D., MHSc, President and Chief Medical Officer of BrainStorm Cell Therapeutics, will provide a corporate and clinical overview at the 12th Annual California ALS Research Summit , which is being held virtually January 27-28, 2022.

Key Points: 
  • NEW YORK, Jan. 27, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Ralph Kern, M.D., MHSc, President and Chief Medical Officer of BrainStorm Cell Therapeutics, will provide a corporate and clinical overview at the 12th Annual California ALS Research Summit , which is being held virtually January 27-28, 2022.
  • The NurOwntechnology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders.
  • MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.
  • About BrainStorm Cell Therapeutics Inc.
    BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.

BrainStorm Cell Therapeutics to Present at Biotech Showcase™ 2022

Retrieved on: 
Tuesday, January 4, 2022
Safety, Association, Annual report, EMA, European Medicines Agency, MS, California Institute for Regenerative Medicine, FDA, Multiple sclerosis, MHSC, Orphan drug, Badminton Association of India, Company, ALS Association, NASDAQ, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, NTFS, Neurodegeneration, Microsoft, Amyotrophic lateral sclerosis, Therapy, Brainstorm, CIRM, Research, Regenerative medicine, Adult, National, Phrase, Pharmaceutical industry, ALS

NEW YORK, Jan. 4, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Ralph Kern, M.D.

Key Points: 
  • NEW YORK, Jan. 4, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Ralph Kern, M.D.
  • MHSc, President and Chief Medical Officer of Brainstorm Cell Therapeutics, will provide a corporate and clinical overview at Biotech Showcase2022 , to be held virtually January 10-12 and 17-18, 2022.
  • The NurOwn technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders.
  • About BrainStorm Cell Therapeutics Inc.
    BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.

BrainStorm Cell Therapeutics and Catalent Announce Completion of Technology Transfer for NurOwn® Manufacturing

Retrieved on: 
Tuesday, December 7, 2021
EMA, NYSE, Company, Research, National, Technology, Therapy, California, Multiple sclerosis, Phrase, Catalent, Neurodegeneration, Safety, Annual report, Food, Regenerative medicine, NTFS, CGMP, Patient, CTLT, Industry, Microsoft, Technology transfer, Partnership, California Institute for Regenerative Medicine, Amyotrophic lateral sclerosis, Brainstorm, MS, European Medicines Agency, FDA, NASDAQ, CIRM, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PMS, Orphan drug, Cell, Pharmaceutical industry

NurOwn will be manufactured at Catalent's world-class 32,000 square-foot cell therapy manufacturing facility in Houston, Texas.

Key Points: 
  • NurOwn will be manufactured at Catalent's world-class 32,000 square-foot cell therapy manufacturing facility in Houston, Texas.
  • "The successful completion of this technology transfer with Catalent is an important step in establishing manufacturing preparedness for NurOwn," said Chaim Lebovits, Chief Executive Officer, Brainstorm Cell Therapeutics.
  • Manja Boerman, Ph.D., President, Catalent Cell & Gene Therapy, said, "Our extensive experience in cell therapy development and scale-up was key to the completion of this technology transfer to our state-of-the-art cell therapy facility in Houston, Texas.
  • About BrainStorm Cell Therapeutics Inc.
    BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.

BrainStorm Cell Therapeutics to Present New Biomarker Data on NurOwn® at the International Symposium on ALS/MND

Retrieved on: 
Thursday, December 2, 2021
International Symposium on Endovascular Therapy, Brainstorm, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, European Medicines Agency, Cell, Biomarker, Phrase, Regenerative medicine, Access, Company, MS, Neurodegeneration, Multiple sclerosis, Microsoft, GMT, MD, Cerebrospinal fluid, Program, University, Neuroinflammation, PCA, Neuroprotection, California Institute for Regenerative Medicine, Therapy, Annual report, EVP, NTFS, Principal component analysis, Machine learning, Research, Publication, EMA, Orphan drug, CSF, FDA, Amyotrophic lateral sclerosis, National, California, CIRM, NASDAQ, Food, University of Massachusetts Medical School, Pharmaceutical industry, Medical imaging

Brainstorm previously announced clinical results from the Phase 3 randomized, placebo control trial which evaluated the safety and efficacy of repeat administrations of NurOwn in ALS.

Key Points: 
  • Brainstorm previously announced clinical results from the Phase 3 randomized, placebo control trial which evaluated the safety and efficacy of repeat administrations of NurOwn in ALS.
  • In the Phase 3 trial, CSF samples were obtained prior to the first treatment and at 6 additional time points.
  • Robust and statistically significant CSF biomarker changes from baseline were observed with NurOwn treatment compared to placebo, particularly in biomarkers related to neuroinflammation, neurodegeneration, and neurotrophic factors.
  • About BrainStorm Cell Therapeutics Inc.
    BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.

MiniTool Partition Wizard 12.6: Brand-new & Enhanced Data Recovery Feature

Retrieved on: 
Monday, November 29, 2021
USB, Windows Server, MiniTool Partition Wizard, NTFS, Microsoft, Program, FAT32, PlayStation, Software, Crash, ExFAT, Data recovery, Cassette tape, Video game console

This new version of MiniTool Partition Wizard is compatible with Windows 11 and mainly comes with a brand-new interface of the Data Recovery feature, and improved data recovery from the FAT32 partition.

Key Points: 
  • This new version of MiniTool Partition Wizard is compatible with Windows 11 and mainly comes with a brand-new interface of the Data Recovery feature, and improved data recovery from the FAT32 partition.
  • MiniTool Partition Wizard 12.6 has redesigned the interface of its built-in Data Recovery feature, making it simpler and more user-friendly.
  • The new version 12.6 of MiniTool Partition Wizard comes with deeply enhanced data recovery from the FAT32 partition.
  • MiniTool Partition Wizard is a professional and reliable disk and partition management program first released by MiniTool Software Limited in 2009.

BrainStorm Cell Therapeutics Announces the Presentation of New Analyses from the Phase 3 Trial of NurOwn® in ALS at the 4th Annual ALS ONE Research Symposium

Retrieved on: 
Monday, November 29, 2021
Research, Patient, Brainstorm, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, European Medicines Agency, Cell, Disease, Phrase, Regenerative medicine, Company, MS, Forbes Norris, Neurodegeneration, Multiple sclerosis, Microsoft, California Pacific Medical Center, Doctor of Philosophy, Therapy, California Institute for Regenerative Medicine, Program, Annual report, NTFS, Publication, EMA, Orphan drug, FDA, Amyotrophic lateral sclerosis, Observation, National, CIRM, NASDAQ, Method, Food, Pharmaceutical industry, Silviculture

NEW YORK, Nov. 29, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the presentation of new analyses from the Phase 3 trial of NurOwn at the 4th Annual ALS ONE Research Symposium .

Key Points: 
  • NEW YORK, Nov. 29, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the presentation of new analyses from the Phase 3 trial of NurOwn at the 4th Annual ALS ONE Research Symposium .
  • The Phase 3 trial of NurOwn in ALS included a higher percentage of participants with advanced ALS at baseline (ALSFRS-R 25) compared to other trials, resulting in a lower baseline mean.
  • The slides from the presentation will be available on the Publications page of Brainstorm's corporate website following the conclusion of the ALS ONE Research Symposium.
  • About BrainStorm Cell Therapeutics Inc.
    BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.

BrainStorm to Announce Third Quarter Financial Results and Provide a Corporate Update

Retrieved on: 
Monday, October 25, 2021
Safety, Orphan drug, Microsoft, Neurodegeneration, European Medicines Agency, Regenerative medicine, NTFS, EMA, FDA, Food, California, Multiple sclerosis, MS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, National, Company, Brainstorm, Amyotrophic lateral sclerosis, Cell, California Institute for Regenerative Medicine, Therapy, CIRM, Pharmaceutical industry

The NurOwntechnology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders.

Key Points: 
  • The NurOwntechnology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders.
  • MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.
  • MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs).
  • About BrainStorm Cell Therapeutics Inc.
    BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.

Centric Token Burn Powered by NFT Collection Sells Out Each of the First 100 NFTs Seconds After Minting--900 More NFTs to Drop Monday

Retrieved on: 
Thursday, October 21, 2021
Well, People, Binance Coin, Blockchain, BSC, Burn, Butcher, Trust, NFT, CA, Burn It Down, MetaMask, CNS, NTFS, Twitter, Partnership, BNB, Adoption, Collection, Centric, Pyromania, Awareness, Attention, COO, Non-fungible token, News, Sale, CNR, Cryptocurrency, Design, Marketing

Pyromaniacs collection were made available to the Centric community in a limited release presale on Airnfts, an NFT marketplace on Binance Smart Chain.

Key Points: 
  • Pyromaniacs collection were made available to the Centric community in a limited release presale on Airnfts, an NFT marketplace on Binance Smart Chain.
  • The NFTs were minted over a three-hour period as Airnfts currently only supports uploading one at a time.
  • The remaining nine hundred NFTs will be released on Airnfts starting Monday, October 25, at 8 AM PST.
  • The lion's share of the profits will go back to the Centric community, in the form of a Centric Rise (CNR) token burn.